KOSDAQBiotech & Pharma304840

PeopleBio

₩561 0.00%2026-11-18 close
Market Cap
₩14.1B
Turnover
₩0
Volume
0 shares
Shares out.
25.1M
PER
—
PBR
0.5×
EPS
-₩1,083
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

A loss-making biotech widening into AI infrastructure

Revenue has risen for three straight quarters through the third quarter of 2026 and operating losses are narrowing, but net losses attributable to controlling shareholders have widened, so the shift to a profitable structure is still in progress.

  1. 1

    After a July 2026 shareholder meeting, the company changed its name to TimeX AI, Inc. (short form TimeX AI) and relisted under the new name on November 3, 2026. Its business is organized around three pillars: AI data center infrastructure and servers, semiconductors, and biotechnology.

  2. 2

    On a disclosed basis, quarterly revenue bottomed at KRW 154 million in the fourth quarter of 2025 and rose to KRW 2.49 billion in the third quarter of 2026, with three consecutive quarterly increases.

  3. 3

    Operating loss narrowed from KRW 2.07 billion in the third quarter of 2025 to KRW 502 million in the third quarter of 2026, yet net loss attributable to controlling shareholders widened to KRW 10.2 billion in the fourth quarter of 2025 and KRW 2.81 billion in the third quarter of 2026. The four-quarter total is KRW 17.1 billion.

  4. 4

    Using KRW 79.2 billion of capital surplus to offset accumulated deficits created a base for future shareholder returns. Total equity at the end of 2025 was KRW 28.6 billion and total liabilities were KRW 16 billion.

  5. 5

    Because the last four quarters show net losses, PER cannot be calculated, while the price-to-book ratio sits below 1x.

02

Business structure

TimeX AI (formerly PeopleBio) changed its name at a July 2026 shareholder meeting and is building out AI infrastructure as a new growth engine. The company organizes its business around three pillars: AI data center infrastructure and servers, semiconductors, and the existing biomedical business.

The core of the biotech segment is AlzOn, a blood-based test for early Alzheimer's disease diagnosis. The product uses an ELISA method that can run on common laboratory plate readers, and the filing cites a Korean consumer supply price of about KRW 100,000, below amyloid PET and cerebrospinal fluid testing.

Biotech segment revenue rose more than 50% quarter on quarter in the second quarter of 2026 and led the recovery, with rental income from a building in Daechi-dong adding support. The flagship AI infrastructure project is a 9MW AI edge data center in the Samsung-dong International Business District in Seoul.

The company participates alongside a co-business partner, sharing project management, core equipment supply and operation, and hosting duties.

The semiconductor segment is negotiating the purchase of used 200mm wafer production equipment, with commercialization targeted for the second half, and it is also working with a refurbishment partner on aging equipment.

The AI and semiconductor businesses are expected to show revenue contribution mainly from the second half of 2026 onward, so the pace of the business restructuring is the key open question.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩2.1B−174.6%
2025Q4₩200M-₩1.7B−1133.8%
2026Q1₩600M-₩1.5B−230.5%
2026Q2₩1.7B-₩700M−44.9%
2026Q3₩2.5B-₩500M−20.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩4.4B-₩11.7B-₩14.3B−263.2%−350.6%614.3%
2023₩4.5B-₩15.2B-₩16B−342.4%−83.6%40.3%
2024₩3.7B-₩11.5B-₩10.9B−308.2%−130.0%255.3%
2025₩2.9B-₩8.4B-₩15.7B−293.9%−54.9%55.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a disclosed annual basis, revenue went from KRW 4.44 billion in 2022 to KRW 4.45 billion in 2023 (up 0.2% year on year), which was the peak year, and then fell to KRW 3.73 billion in 2024 (down 16.2%) and KRW 2.85 billion in 2025 (down 23.6%), declining for two consecutive years.

Among 2022 to 2025, 2023 was the largest year and 2025 was the smallest. Operating loss was KRW 11.7 billion in 2022, KRW 15.2 billion in 2023, KRW 11.5 billion in 2024 and KRW 8.38 billion in 2025, a loss in each of the four years.

The operating margin was -263.2% in 2022, -342.4% in 2023, -308.2% in 2024 and -293.9% in 2025. Net loss attributable to controlling shareholders was KRW 14.3 billion in 2022, KRW 16 billion in 2023, KRW 10.9 billion in 2024 and KRW 15.7 billion in 2025, also a loss in each of the four years.

In 2025 the operating loss narrowed while the net loss attributable to controlling shareholders widened, and the net loss including non-controlling interests was KRW 16.9 billion. That gap suggests non-operating items weighed heavily, though the detailed causes should be checked in the notes to the periodic report.

Quarterly revenue fell from KRW 1.18 billion in the third quarter of 2025 to KRW 154 million in the fourth quarter (down 87.0% quarter on quarter), then rose to KRW 643 million in the first quarter of 2026, KRW 1.67 billion in the second quarter and KRW 2.49 billion in the third quarter, with three consecutive quarterly increases.

Third-quarter revenue was up 110.0% year on year. In its preliminary second-quarter release, the company reported revenue up 128% year on year. Operating loss narrowed from KRW 2.07 billion in the third quarter of 2025 to KRW 502 million in the third quarter of 2026, a five-quarter run of losses.

Net loss attributable to controlling shareholders, however, widened to KRW 10.2 billion in the fourth quarter of 2025 and then to KRW 2.81 billion in the third quarter of 2026, and the four-quarter total is KRW 17.1 billion.

With operating losses shrinking but net losses growing, non-operating items and one-off factors are the main items to verify in the next periodic report.

05

Industry analysis

Demand for AI data centers starts with investment plans at large chipmakers.

Samsung Electronics is running a roadmap to build an intelligent semiconductor fab with AI embedded across the entire process, and SK hynix has made visible a 15GW-scale large data center investment, which the company sees as lifting demand across the related value chain.

Edge data centers are facilities built in urban areas close to where data is generated, minimizing response latency.

Large groups including SK and other major internet and conglomerate players are accelerating large-scale AI data center builds, while smaller AI infrastructure specialists are entering edge data centers, making competition increasingly polarized.

Smaller operators tend to differentiate through urban locations and leasing and hosting structures rather than matching scale.

The co-business partner is reported to aim for a high-margin model based on colocation rental and fixed-fee cross-connect revenue, comparable to the neutral network service model of a major subsidiary of a Korean internet group.

In semiconductors, refurbishment involves refitting aging equipment, and the company is adding specialist staff and engineering capacity to respond to custom orders. In biotech, the blood-based Alzheimer's test positions itself as a lower-cost alternative to amyloid PET and cerebrospinal fluid testing.

Given the large scale gap with dedicated AI infrastructure players, results depend heavily on the start of specific projects and the rental income structure. Insurance coverage and the speed of sales channel expansion are variables to check in upcoming results.

06

Outlook

The company expected revenue from its semiconductor segment to become visible from the second half of 2026 and AI-related revenue to expand, while AlzOn sales were expected to rise during the health checkup season.

It said that a full semiconductor revenue contribution, AI business expansion and continued biotech growth together would speed up the earnings turnaround.

For the 9MW edge data center in Samsung-dong, the timetable called for an electricity supply contract with the power utility around August 2026, a project financing target at the end of September, and construction to begin in October.

The co-business partner said it raised KRW 15 billion of operating funds from a real estate asset manager affiliated with a Korean financial group.

The same partner estimated the facility could generate more than KRW 28 billion in annual operating revenue and a business value of about KRW 400 billion, although this is the partner's own estimate.

In semiconductors, talks on acquiring used 200mm equipment are ongoing, with commercialization targeted for the second half. In biotech, the company filed for FDA Breakthrough Device designation and aimed for approval by August 2026.

Since that target month has passed, the company's disclosure of the designation outcome is the next checkpoint. The fourth-quarter 2026 preliminary results and the 2026 annual report will show whether the non-operating structure becomes clearer and whether the profit trend holds.

07

Valuation

PER
—
PBR
0.5×
ROE
-117.8%
EPS
-₩1,083
BPS
₩1,195
Dividend per share
₩0

The net loss attributable to controlling shareholders totals KRW 17.1 billion over the last four quarters, so PER cannot be calculated on an earnings basis. The price-to-book ratio sits below 1x, meaning the shares trade below book net asset value. The dividend yield is well below the industry average.

The July 2026 capital surplus offset of accumulated deficits created a foundation for future dividends. However, the deficit offset reduces only the reported accumulated loss, and actual dividend capacity depends on narrowing net losses and improving operating cash flow.

Operating cash flow was KRW -5.17 billion in 2025, a smaller deficit than KRW -10.9 billion in 2024. Listed peers in biopharma can be compared on multiples based on therapeutic or biopharmaceutical sales, but this company mixes AI infrastructure and rental income, which limits simple multiple comparisons.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Revenue up for three straight quarters

Revenue rebounded from KRW 154 million in the fourth quarter of 2025 to KRW 643 million, KRW 1.67 billion and KRW 2.49 billion over the next three quarters. Third-quarter revenue rose 110.0% year on year. The company said its biotech revenue rose more than 50% quarter on quarter and led the improvement.

Narrowing operating losses

Operating loss narrowed from KRW 2.07 billion in the third quarter of 2025 to KRW 502 million in the third quarter of 2026. On an annual basis, the 2025 operating loss of KRW 8.38 billion was smaller than KRW 11.5 billion in 2024.

The operating margin improved to -293.9% in 2025 from -342.4% in 2023, and the loss has been narrowing clearly even though the company remains in deficit.

AI infrastructure progress and balance-sheet cleanup

The 9MW AI edge data center in Samsung-dong is progressing, and the company said it is preparing for main construction and completing power connection procedures. Offsetting accumulated deficits with KRW 79.2 billion of capital surplus is also a step in balance-sheet cleanup.

09

Bear factors

Widening net loss attributable to controlling shareholders

Even as operating loss narrowed, the net loss attributable to controlling shareholders widened to KRW 2.81 billion in the third quarter of 2026 from the prior quarter. It reached KRW 10.2 billion in the fourth quarter of 2025, and the four-quarter total is KRW 17.1 billion.

If non-operating items are dragging on earnings, operating improvement will not translate directly into a smaller net loss.

Small revenue base after two years of decline

Revenue in 2025 was KRW 2.85 billion, below the KRW 4.45 billion peak in 2023, and it declined in both 2024 and 2025. The debt ratio fell to 55.7% in 2025 from 255.3% in 2024, and total liabilities at the end of 2025 were KRW 16 billion. With a small revenue base, slower recognition of new business revenue could slow the recovery.

Project timing and competitive intensity

The edge data center's project financing and construction start were initially timed for September and October. The FDA Breakthrough Device designation was targeted for August 2026.

With large groups expanding AI data center investment, competition for smaller operators is intensifying, and any schedule delay would push back the timing of revenue recognition.

10

Risk factors

Financing and project timing

The edge data center depends on project financing. The co-business partner has raised KRW 15 billion of operating funds, but the scale and timing of the main project financing need to be confirmed through disclosure. If the original schedule slips, the timing of new revenue recognition will also be delayed.

Regulatory and permitting

The FDA designation process involved supplemental responses to additional questions from the agency. The designation outcome could change the sales strategy for AlzOn and the timing of US market access. Electricity supply contracts and construction permits for the data center are also schedule variables.

Earnings volatility

Quarterly revenue has swung widely, from KRW 154 million in the fourth quarter of 2025 to KRW 2.49 billion in the third quarter of 2026, reflecting a still-small revenue base.

Large non-operating items make net loss move differently from operating loss, and semiconductor refurbishment results will depend on equipment acquisition and order volume.

11

What to watch next

  1. End of December 2026

    Whether the used 200mm wafer equipment acquisition and second-half commercialization move forward. Whether the plan to accelerate second-half commercialization appears in equipment disclosures or revenue by year-end is the checkpoint.

  2. Around January 2027 (expected timing of preliminary results)

    Fourth-quarter 2026 revenue and net loss attributable to controlling shareholders. Whether revenue growth continues for a fourth straight quarter and whether the net loss widens sharply as it did in the fourth quarter of 2025 are the points to watch.

  3. End of March 2027 (annual report filing deadline)

    The 2026 annual report will show the composition of non-operating items, equity and liabilities, and the change in operating cash flow. Whether the narrowing operating loss carries through to a smaller net loss is the benchmark for the shift in earnings structure.

  4. Timing undetermined (on disclosure)

    Disclosure of the main project financing and construction start for the Samsung-dong edge data center. Since the original outlook called for main financing at the end of September and construction in October, whether the schedule has changed is important.

  5. Timing undetermined (on disclosure)

    The outcome of the FDA Breakthrough Device designation. Since the company aimed for approval by August 2026, the disclosure of the result is a key variable for the biotech outlook.

12

Overall view

TimeX AI (formerly PeopleBio) is shifting from a diagnostics-focused biotech into a three-pillar business that adds AI infrastructure and semiconductors.

On a disclosed basis, 2025 revenue of KRW 2.85 billion was the smallest in the period, but revenue has risen for three straight quarters since the first quarter of 2026 and operating losses have been narrowing.

Strengths include the revenue rebound, the narrowing operating loss, the dividend foundation created by offsetting KRW 79.2 billion of accumulated deficits, and progress on new projects such as the Samsung-dong edge data center.

On the other side, net loss attributable to controlling shareholders widened to KRW 10.2 billion in the fourth quarter of 2025 and KRW 2.81 billion in the third quarter of 2026, with a four-quarter total of KRW 17.1 billion.

The size and nature of non-operating items should be checked in the notes to the periodic report. Much of the new business depends on a partner's estimates and earlier timetables, so the timing of project financing and the FDA outcome matter.

The next checkpoints are the fourth-quarter 2026 preliminary results, the structure of the net loss in the 2026 annual report, the disclosure of main financing and construction for the edge data center, and the FDA designation outcome.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thebionews.net
  2. greened.kr
  3. thedailypost.kr
  4. edaily.co.kr
  5. greened.kr
  6. thebionews.net
  7. ebn.co.kr
  8. news.nate.com
  9. view.asiae.co.kr
  10. dealsite.co.kr
  11. topstarnews.net
  12. tipranks.com
  13. news.nate.com
  14. edaily.co.kr
  15. marketin.edaily.co.kr
  16. en.edaily.co.kr
  17. m.sedaily.com
  18. ftest.edaily.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis